CPH Insider Trading

Insider Ownership Percentage: 42.65%
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$34,100.00

Cipher Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Cipher Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cipher Pharmaceuticals Share Price & Price History

Current Price: C$3.30
Price Change: Price Decrease of -0.04 (-1.20%)
As of 03/31/2023 01:00 AM ET

This chart shows the closing price history over time for CPH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Cipher Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2022Christian GodinDirectorSell4,000C$3.90C$15,600.0099,210
12/7/2022Christian GodinDirectorSell5,000C$3.70C$18,500.00106,210
See Full Table

SEC Filings (Institutional Ownership Changes) for Cipher Pharmaceuticals (TSE:CPH)

0.20% of Cipher Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cipher Pharmaceuticals logo
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
Read More on Cipher Pharmaceuticals

Today's Range

Now: C$3.30
Low: C$3.21
High: C$3.35

50 Day Range

MA: C$3.59
Low: C$3.30
High: C$3.87

52 Week Range

Now: C$3.30
Low: C$2.00
High: C$4.07


46,760 shs

Average Volume

14,831 shs

Market Capitalization

C$82.76 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Cipher Pharmaceuticals?

Cipher Pharmaceuticals' top insider shareholders include:
  1. Christian Godin (Director)
Learn More about top insider investors at Cipher Pharmaceuticals.